Jun 2026 (Q2 FY26) — Aug 5, 2026
LifeMD, Inc. Q2 FY26 — Strategic Shift Towards Quality Revenue and Diversified Growth
Read the full callLifeMD (LFMD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
LifeMD earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 47.3 | −3.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -15.1 | −10.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.25 −3.85% · −$0.09
Performance −63.0% 1Y
1Y: $6.08 on 17 Oct 2025 → $2.25. High $6.3 (24 Oct 2025), low $2.25 (19 Oct 2026).
- Previous close
- $2.34
- 52-week range
- $2.25 – $6.3
- One year
- −63.83%
Overview
- Symbol
- LFMD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
LifeMD earnings calls (LFMD)
Financials
What the filings say
Net profit, year on year: −337% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 53 | 64 | 51 | 49 | 60 | 7 | 50 | 47 |
| Operating profit | -4 | 1 | -1 | -2 | -2 | -6 | -9 | -7 |
| Operating margin | −7.5% | 1.6% | −2.3% | −4.8% | −3.3% | −87.9% | −17.8% | −15.1% |
| Interest | 1 | 1 | 0 | 1 | 0 | -0 | -0 | -0 |
| Profit before tax | -5 | 0 | -2 | -3 | -3 | — | -9 | -7 |
| Tax rate | −5.1% | 41.9% | — | — | −5.0% | — | — | — |
| Net profit | -5 | -0 | -0 | -2 | -4 | 20 | -9 | -7 |
| EPS ($ per share) | -0.13 | — | -0.02 | -0.05 | — | — | -0.20 | -0.16 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -12 | -17 | -80 | -142 | -191 | -214 | -240 | -229 |
| Total liabilities | 2 | 5 | 14 | 24 | 33 | 53 | 84 | 47 |
| Fixed assets | — | — | — | 0 | 0 | 0 | 1 | 2 |
| Total assets | 3 | 3 | 13 | 50 | 26 | 58 | 76 | 70 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1 | 0 | -12 | -33 | -23 | 9 | 18 | 8 |
| Cash from investing | 0 | -0 | -1 | -3 | -14 | -9 | -12 | 7 |
| Cash from financing | 1 | 1 | 21 | 69 | -1 | 29 | -4 | -13 |
| Net cash flow | 0 | 1 | 8 | 32 | -37 | 29 | 2 | 2 |
| Capital expenditure | — | — | — | -0 | -0 | -0 | -1 | -2 |
| Free cash flow | — | — | — | -33 | -23 | 9 | 16 | 6 |
Insider filings
11 filings between Dec 9, 2025 and Aug 11, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$54.2K
1 sale by 1 insider
Compensation
not trading decisions- 10
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| FRIEDEMAN JESSICA | — | $54.2K | Dec 9, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Strawn John R Jr Director | Award | 35,000 | $0 |
| Aug 11, 2026 | LAROVERE JOAN Director | Award | 35,000 | $0 |
| Aug 11, 2026 | Simon Roberto Director | Award | 35,000 | $0 |
| Aug 11, 2026 | MACRAE CALUM ARCHIBALD Director | Award | 35,000 | $0 |
| Aug 11, 2026 | DiTrolio Joseph Director | Award | 35,000 | $0 |
| Jun 1, 2026 | Sripad Umesh Chief Technology Officer | Award | 75,000 | $0 |
| May 11, 2026 | Kavthekar Atul Chief Financial Officer | Award | 337,500 | $0 |
| May 4, 2026 | Strawn John R Jr Director | Award | 50,000 | $0 |
| May 4, 2026 | Simon Roberto Director | Award | 50,000 | $0 |
| Mar 30, 2026 | Pisano Christopher A Chief Marketing Officer | Award | 200,000 | $0 |
| Dec 9, 2025 | FRIEDEMAN JESSICA Chief Marketing Officer | Sale | 15,000 | $54.2K |
| Oct 6, 2025 | Strawn John R Jr Director | Award | 22,365 | $0 |
| Oct 6, 2025 | LAROVERE JOAN Director | Award | 22,365 | $0 |
| Oct 2, 2025 | MACRAE CALUM ARCHIBALD Director | Award | 22,365 | $0 |
| Oct 2, 2025 | DiTrolio Joseph Director | Award | 22,365 | $0 |
| Oct 2, 2025 | Simon Roberto Director | Award | 22,365 | $0 |
| Sep 10, 2025 | Alvarez Nicholas P Chief Acquisition Officer | Sale | 75,000 | $443.8K |
| Aug 22, 2025 | Yecies Eric Harold Chief Legal Officer & GC | Award | 50,000 | $0 |
| Aug 22, 2025 | Galluppi Stefan Chief Innovation Officer | Award | 30,000 | $0 |
| Aug 22, 2025 | STAN MARIA E. Chief Accounting Officer | Award | 20,000 | $0 |
| Aug 22, 2025 | Wijnker Dennis Chief Technology Officer | Award | 25,000 | $0 |
| Aug 22, 2025 | Dray Shayna Webb Chief Operating Officer | Award | 30,000 | $0 |
| Aug 22, 2025 | Alvarez Nicholas P Chief Acquisition Officer | Award | 100,000 | $0 |
| Aug 22, 2025 | Benathen Marc David Chief Financial Officer | Award | 87,000 | $0 |
| Aug 22, 2025 | FRIEDEMAN JESSICA Chief Marketing Officer | Award | 50,000 | $0 |
| Jul 27, 2025 | Dray Shayna Webb Chief Operating Officer | Award | 50,000 | $0 |
| Jul 1, 2025 | Schreiber Justin Chairman and CEO | Sale 10b5-1 plan | 25,000 | $249.7K |
| Jul 1, 2025 | Schreiber Justin Chairman and CEO | Sale 10b5-1 plan | 25,000 | $334.5K |
| Jun 17, 2025 | Benathen Marc David Chief Financial Officer | Sale 10b5-1 plan | 50,000 | $700.5K |
| Jun 16, 2025 | Benathen Marc David Chief Financial Officer | Sale 10b5-1 plan | 75,000 | $981.9K |
| Jun 13, 2025 | Yecies Eric Harold Chief Legal Officer & GC | Sale | 15,000 | $183.8K |
| Jun 13, 2025 | Galluppi Stefan Chief Innovation Officer | Sale 10b5-1 plan | 85,000 | $1.05M |
| Jun 2, 2025 | Schreiber Justin Chairman and CEO | Sale 10b5-1 plan | 25,000 | $311.7K |
| May 2, 2025 | Schreiber Justin Chairman and CEO | Sale 10b5-1 plan | 3,005 | $22.5K |
| May 1, 2025 | Schreiber Justin Chairman and CEO | Sale 10b5-1 plan | 21,995 | $165.7K |
| Apr 29, 2025 | Schreiber Justin Chairman and CEO | Sale 10b5-1 plan | 50,000 | $389.0K |
| Mar 31, 2025 | STAN MARIA E. Chief Accounting Officer | Award | 20,000 | $0 |
| Mar 31, 2025 | STAN MARIA E. Chief Accounting Officer | Award | 20,000 | $0 |
| Mar 31, 2025 | Alvarez Nicholas P Chief Acquisition Officer | Award | 75,000 | $0 |
| Mar 31, 2025 | Galluppi Stefan Chief Innovation Officer | Award | 30,000 | $0 |
| Mar 31, 2025 | Benathen Marc David Chief Financial Officer | Award | 75,000 | $0 |
| Mar 31, 2025 | Yecies Eric Harold Chief Legal Officer & GC | Award | 30,000 | $0 |
| Mar 31, 2025 | Yecies Eric Harold Chief Legal Officer & GC | Award | 18,750 | $0 |
| Mar 31, 2025 | Wijnker Dennis Chief Technology Officer | Award | 25,000 | $0 |
| Mar 19, 2025 | Schreiber Justin Chairman and CEO | Gift | 13,997 | $0 |
| Mar 19, 2025 | Schreiber Justin Chairman and CEO | Gift | 27,994 | $0 |
| Mar 19, 2025 | Schreiber Justin Chairman and CEO | Gift | 13,997 | $0 |
| Mar 14, 2025 | FRIEDEMAN JESSICA Chief Marketing Officer | Sale | 30,000 | $169.7K |
| Mar 7, 2025 | Benathen Marc David Chief Financial Officer | Award | 87,000 | $0 |
| Mar 7, 2025 | Galluppi Stefan Chief Innovation Officer | Award | 30,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LifeMD, Inc.
Free account. Everything above stays public.
Write why you follow LifeMD, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading